News

The successful development of Sistemic’s SistemPSCCheck™ assay is featured as case studies on both the Innovate UK Analysis for Innovators website and the National Measurement Laboratory for Chemical and Bio-Measurement at LGC website

Release Date: March 25, 2019

SistemPSCCheck™ is a first-in-class miRNA-based assay, for high sensitivity assessment of residual undifferentiated PSCs in derived cell preparations. SistemPSCCheck™ is a safety and batch release assay service to support the clinical and commercial development of pluripotent stem cell-derived cell therapy products.

SistemPSCCheck™ was developed in conjunction with National Measurement Laboratory for Chemical and Bio-Measurement at LGC and was supported by the UK’s innovation agency, Innovate UK, under the “Analysis for Innovators” grant.

Sistemic Ltd announce expansion of patent portfolio covering the use of microRNAs for quality assessment of stem cell therapy products

Release Date: January 28, 2019

Glasgow, United Kingdom; 28th January 2019: Sistemic Ltd. is pleased to announce that it has received Notification of Intention to Grant by the European Patent Office for the patent application entitled “Cell Characterisation” (European Patent Application No 11760806.7).

The patent covers the use of microRNA profiles for quality assessment of stem cells and derived cell therapy products.

Sistemic Ltd. announce a milestone Global Service and License Agreement with Cynata Therapeutics Ltd. for the use of its SistemPSCCheck™ assay as part of the QCS release testing for CYP-001 and Cynata’s planned range of iPSC-derived products

Release Date: October 22, 2018

Glasgow, United Kingdom; 22nd October 2018: Sistemic Ltd. is pleased to announce the completion of a Global Service and License Agreement for its SistemPSCCheck™ assay with Australian stem cell and regenerative medicine company, Cynata Therapeutics Ltd. The agreement will see the use of the SistemPSCCheck™ assay for the assessment of residual pluripotent stem cells in Cynata’s current iPSC-derived MSC clinical candidate CYP-001, as well other planned iPSC-derived MSC products.

Pages